121 related articles for article (PubMed ID: 37639838)
1. The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study.
Zhang J; Zhao R; Xu H; Dong L; Chen X
Ann Diagn Pathol; 2023 Dec; 67():152192. PubMed ID: 37639838
[TBL] [Abstract][Full Text] [Related]
2. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
Chen J; Zheng Q; Wang J; Zhang X; Lv Y
Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
[TBL] [Abstract][Full Text] [Related]
5. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
6. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
PeerJ; 2024; 12():e16923. PubMed ID: 38374950
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
[TBL] [Abstract][Full Text] [Related]
9. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
[TBL] [Abstract][Full Text] [Related]
10. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
13. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y; Decroix E; Blons H; Alifano M; Leroy K; Petitprez F; Boni A; Garinet S; Biton J; Cremer I; Wislez M; Boudou-Rouquette P; Arrondeau J; Goldwasser F; Fournel L; Damotte D; Mansuet-Lupo A
Lung Cancer; 2022 Jul; 169():13-21. PubMed ID: 35597058
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features.
Matsubara D; Kishaba Y; Ishikawa S; Sakatani T; Oguni S; Tamura T; Hoshino H; Sugiyama Y; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
Cancer Sci; 2013 Feb; 104(2):266-73. PubMed ID: 23163725
[TBL] [Abstract][Full Text] [Related]
15. BRG1, INI1, and ARID1B Deficiency in Endometrial Carcinoma: A Clinicopathologic and Immunohistochemical Analysis of a Large Series From a Single Institution.
Kihara A; Amano Y; Matsubara D; Fukushima N; Fujiwara H; Niki T
Am J Surg Pathol; 2020 Dec; 44(12):1712-1724. PubMed ID: 32910019
[TBL] [Abstract][Full Text] [Related]
16. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
17. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
Mao R; Liu M; Shu X; Li W; Yan W; Li X
Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
[No Abstract] [Full Text] [Related]
18. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological features and prognosis of SMARCA4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
[No Abstract] [Full Text] [Related]
20. Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma.
Ogunbona OB; Lin X; Hornick JL; Lubin DJ; Wang Q; Reid MD; Schneider F; Li D; Shin DM; Shi Q
J Am Soc Cytopathol; 2022; 11(4):183-193. PubMed ID: 35491322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]